NASDAQ: HSDTHelius Medical Technologies Inc Stock
$0.60-0.02 (-3.23%)
Updated Dec 6, 2024
HSDT Price
$0.60
Fair Value Price
$0.53
Market Cap
$2.24M
52 Week Low
$0.37
52 Week High
$9.50
P/E
-0.11x
P/B
0.59x
P/S
4.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$502.00k
Earnings
-$8.86M
Gross Margin
-3.2%
Operating Margin
-1,761.95%
Profit Margin
-1,764.7%
Debt to Equity
0.47
Operating Cash Flow
-$11M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HSDT Overview
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HSDT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Value
C
Growth
F
Momentum
C
Sentiment
C
Safety
F
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important HSDT news, forecast changes, insider trades & much more!
HSDT News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSDT ($0.60) is overvalued by 12.99% relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HSDT ($0.60) is not significantly undervalued (12.99%) relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HSDT due diligence checks available for Premium users.
Valuation
HSDT fair value
Fair Value of HSDT stock based on Discounted Cash Flow (DCF)
Price
$0.60
Fair Value
$0.53
Overvalued by
12.99%
HSDT ($0.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HSDT ($0.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
36.83x
Market
29.86x
HSDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
4.05x
HSDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSDT's financial health
Profit margin
Revenue
$51.0k
Net Income
-$3.7M
Profit Margin
-7,227.5%
HSDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSDT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.6M
Liabilities
$1.8M
Debt to equity
0.47
HSDT's short-term assets ($5.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSDT's short-term assets ($5.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSDT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HSDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$0.0
Financing
-$149.0k
HSDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSDT vs Medical Device Stocks
Helius Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.